FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2

Qin Ryan(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), John R. Johnson(Santa Barbara Museum of Natural History), Amna Ibrahim(Beni-Suef University), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Chia‐Wen Ko(United States Food and Drug Administration), Martin H. Cohen(United States Food and Drug Administration), Robert Justice(United States Food and Drug Administration)
The Oncologist
October 1, 2008
10.1634/theoncologist.2008-0816
Cited by 310

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
|PubMed|2001|861